Astigmatism

Bausch + Lomb Receives Health Canada Approval for enVista® Envy™* Full Visual Range Intraocular Lens

Retrieved on: 
tisdag, maj 28, 2024
Biotechnology, Pharmaceutical, Optical, Health, FDA, Medical Devices, Clinical Trials, Other Health, Presbyopia, Patient, Cataract, University, Envy, Astigmatism, Sale, Trial of the century, GLARE, DSM-IV codes, Contact, Dioptre, Bausch & Lomb, Health Canada, Freedom

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Health Canada has approved the enVista® Envy™* full visual range intraocular lens (IOL).

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Health Canada has approved the enVista® Envy™* full visual range intraocular lens (IOL).
  • This is the first global regulatory approval of the new lens, which offers a full range of vision with excellent dysphotopsia tolerance on the widely used enVista IOL platform.
  • “enVista Envy is the next step in the dramatic transformation of our IOL portfolio,” said Luc Bonnefoy, president, Global Surgical, Bausch + Lomb.
  • Bausch + Lomb is also in the process of seeking regulatory approvals for the lens in additional markets, including the U.S. and Europe.

Bausch + Lomb Announces Presentation of New Scientific Data and Evaluations Featuring Consumer, Vision Care and Pharmaceutical Products at Optometry’s Meeting®

Retrieved on: 
tisdag, maj 28, 2024
Research, General Health, Pharmaceutical, Optical, Specialty, Retail, Clinical Trials, Science, Surgery, Medical Supplies, FDA, Health, The Bell Tower, Trial of the century, Viral, Bausch, Allergy, OD, Inflammation, Steroid, Fungal infection, Action, OnDemand, AOA, Telecanthus, CDT, Glaucoma, Sclera, Infection, Intraocular pressure, Contact, American Optometric Association, Conjunctiva, Cerebral edema, Music City Center, Macular edema, Complex, Eye injury, Thought, System, Employment, Convention, Contact lens, Slit lamp, Vaccinia, Patient, Incidence, Safety, Keratitis, Bausch & Lomb, Herpes simplex, Visual acuity, Taste, Iris, Eyelash, Risk, IOP, Lens (vertebrate anatomy), Astigmatism, Pigment, Efficacy, Verge, Ocular hypertension, Eye, Abstract, Human, Pain, Optic nerve, History, Palm, Chickenpox, EYE

The OnDemand ePosters will feature new data on the early adoption of MIEBO and real-world patient experiences with Bausch + Lomb INFUSE® Multifocal silicone hydrogel daily disposable contact lenses.

Key Points: 
  • The OnDemand ePosters will feature new data on the early adoption of MIEBO and real-world patient experiences with Bausch + Lomb INFUSE® Multifocal silicone hydrogel daily disposable contact lenses.
  • “Evaluation of the Efficacy of a Novel Preservative-Free Formulation of Brimonidine Tartrate Ophthalmic Solution.” Evans et al.
  • “Improvement in Non-Invasive Tear Break-Up Time after Instillation of One Drop of Brimonidine Tartrate 0.025%.” Moore et al.
  • During the event, attendees will have the opportunity to learn about Bausch + Lomb’s latest innovations, including Bausch + Lomb INFUSE® for Astigmatism and Blink NutriTears.

STAAR Surgical Reports First Quarter 2024 Results

Retrieved on: 
tisdag, maj 7, 2024
General Health, Surgery, Medical Devices, Health, Optical, Sale, Near-sightedness, Table, IOL, Presbyopia, Investment, EVO, Research, Depreciation, STAAR, ICL, Patient, Access, Marketing, Adjustment, Fruit, Cataract, Advertising, Astigmatism, GAAP, Growth

STAAR Surgical Company (NASDAQ: K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the first quarter ended March 29, 2024.

Key Points: 
  • STAAR Surgical Company (NASDAQ: K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the first quarter ended March 29, 2024.
  • Gross profit margin for the first quarter of 2024 was 78.9% of net sales compared to the prior year quarter of 78.3% of net sales.
  • Product and country mix favorably impacted gross margin in the first quarter of 2024 as compared to the prior year quarter.
  • Operating expenses for the first quarter of 2024 were $63.3 million compared to the prior year quarter of $54.8 million.

STAAR Surgical Announces Milestone Strategic Agreement in U.S. with IQ Laser Vision

Retrieved on: 
tisdag, maj 7, 2024
Optical, Health, Surgery, Medical Devices, Education, Near-sightedness, Left, Presbyopia, EVO, Refractive surgery, Cataract, PIB, STAAR, Surgeon, Nave, MD, Quality, ICL, Contact, Chairperson, Lens, ASCRS, Eye, Society, Athlete, Multimedia, Marketing, SMILE, Astigmatism, Growth, Telescopic sight

View the full release here: https://www.businesswire.com/news/home/20240507036972/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240507036972/en/
    Tom Frinzi, Chair of the Board, President and CEO, STAAR Surgical (Left) and Dr. Robert T. Lin, founder and surgeon, IQ Laser Vision (Right).
  • (Photo: Business Wire)
    IQ Laser Vision will make EVO ICL lenses a primary option for patients seeking surgical vision correction within the range of -3D to -20D, as part of its comprehensive refractive offering.
  • IQ Laser Vision intends to nearly double its volume in EVO ICLs over the course of the next 12 months.
  • Today, we’re thrilled to announce that IQ Laser Vision has joined our U.S. Highway 93 program with the largest agreement for EVO ICL in the U.S. thus far.

GOOD Vision Unveils K-Shape™: A Revolutionary Corneal Topographer at The International Exhibition of Inventions of Geneva

Retrieved on: 
fredag, maj 3, 2024
COVID, Corneal opacity, Astigmatism, News, KONG, Finance, Research, Workflow, Optometry, Invention, Patient, Approximation error, Corneal topography, Data analysis, Health, Diagnosis, Algorithm, Growth, Technical, World's fair

The innovative topographer outperforms existing devices with its flexibility, compact size, utilisation of normative data from Chinese populations, and affordability.

Key Points: 
  • The innovative topographer outperforms existing devices with its flexibility, compact size, utilisation of normative data from Chinese populations, and affordability.
  • Dr. Jason Lau, the Technical Director at GOOD Vision, said, "At GOOD Vision, we're setting new standards in eye care with K-ShapeTM.
  • The debut of GOOD Vision's corneal topographer marks a transformative moment in the industry, significantly enhancing practitioners' ability to deliver personalised care.
  • GOOD Vision invites attendees to visit their booth at The International Exhibition of Inventions of Geneva to experience first-hand the future of corneal topography.

STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel

Retrieved on: 
onsdag, maj 1, 2024
Optical, Health, Surgery, Medical Devices, Corporation, Science, Medtech, Near-sightedness, Law, University, Presbyopia, American Tower, Believer, EVO, General counsel, OTC, Marketing, Commerce, Johnson & Johnson, STAAR, Surgeon, University School, Business, Partner (business rank), CareFusion, Contact, Duke University, NuVasive, Senior, Patient, Multimedia, Global marketing, Emory University, Associate, Astigmatism, Economics, Nate, Growth, Engineering, Management

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel.
  • View the full release here: https://www.businesswire.com/news/home/20240501408389/en/
    “We are thrilled to strengthen the STAAR team with the addition of Nancy and Nate, two seasoned executives with extensive senior leadership experience.
  • “Nancy is a perfect fit for the newly created Chief Marketing Officer position and will be critical to driving our brand awareness and innovation globally.
  • “I am thrilled to join the STAAR leadership team at a time of significant opportunity and growth for our vision correction lenses,” said Nate Sisitsky.

STAAR Surgical to Report First Quarter Results on May 7, 2024

Retrieved on: 
måndag, april 29, 2024
Optical, Health, Surgery, Medical Devices, Near-sightedness, STAAR, Presbyopia, Astigmatism, Webcast, EVO

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the first quarter ended March 29, 2024, on Tuesday, May 7, 2024, after the market close.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the first quarter ended March 29, 2024, on Tuesday, May 7, 2024, after the market close.
  • STAAR will host a conference call and webcast on Tuesday, May 7 at 4:15 p.m. Eastern / 1:15 p.m. Pacific to discuss its financial results and operational progress.
  • To access the conference call please dial 833-816-1164 for domestic participants and 412-317-1899 for international participants.
  • The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com .

STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024

Retrieved on: 
torsdag, april 4, 2024
Optical, Health, Surgery, Medical Devices, ICL, U.S. FDA, Growth, Presbyopia, Near-sightedness, Sale, EVO, Bank statement, Investment, FDA, Astigmatism

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced preliminary net sales for the first quarter ended March 29, 2024, are expected to be in excess of $77 million with U.S. ICL sales expected to be $5 million for the quarter.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced preliminary net sales for the first quarter ended March 29, 2024, are expected to be in excess of $77 million with U.S. ICL sales expected to be $5 million for the quarter.
  • “STAAR is off to a solid start in 2024 as illustrated by our preliminary first quarter results including a record quarter in the U.S.,” said Tom Frinzi, President and CEO of STAAR Surgical.
  • ICL sales were up approximately 20% sequentially to $5 million in the first quarter, which reflects early signs of our increased market focus.
  • The Company expects to report complete first quarter financial results and discuss its fiscal 2024 outlook during its quarterly earnings call on or about May 8, 2024.

STAAR Surgical Celebrates Three Million Lens Milestone at ASCRS Meeting, Unveils New EVO ICL Data and Latest Innovation for 2024

Retrieved on: 
tisdag, april 2, 2024
Biotechnology, Practice Management, Optical, Surgery, General Health, Health, Hospitals, Other Health, Presbyopia, ASCRS, Patient, Social media, Near-sightedness, Lens, Cataract, Astigmatism, EVO, STAAR, Surgeon, Publication, Society, Booth, FACS, Multimedia, Behavior, FDA, Reflexive relation, Communications satellite

Furthering the momentum behind its flagship product, EVO ICL, the company is proud to showcase the clinical, practice and innovation advantages through a series of posters, presentations and educational programs.

Key Points: 
  • Furthering the momentum behind its flagship product, EVO ICL, the company is proud to showcase the clinical, practice and innovation advantages through a series of posters, presentations and educational programs.
  • STAAR Surgical can be found at Booth 527 and additional ASCRS event information is available at https://ascrs.org/annual-meeting .
  • View the full release here: https://www.businesswire.com/news/home/20240402599401/en/
    “EVO ICL is the next logical step in refractive innovation.
  • The website offers surgeons access to a wealth of resources, including publications, key clinical outcomes data, and more.

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
onsdag, mars 27, 2024
Science, Other Science, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Momentum, YAG, Toric, Failure, IOP, Retinal, Glaucoma, Exercise, DSM-IV codes, Neuropathic pain, ASCRS, History, Sale, Contact, Dry, Refraction, Bausch & Lomb, Eye, System, Keratoconus, Medication discontinuation, Pain, Corneal topography, Telecanthus, Astigmatism, Aphakia, Correction, Uveitis, Surgeon, Diabetes, Risk, Eye injury, CTK, Retinal detachment, Side, Trial of the century, Visual acuity, Diagnosis, Safety, Contraindication, Emmetropia, Vision, Taste, Dry eye syndrome, Intraocular lens, Presbyopia, Real, Floater, Magnetic resonance, Contrast (vision), Human, GLARE, Infection, Use, FDA, Ranibizumab, Muscular dystrophy, Sickle cell disease, Refractive surgery, Retina, Direction, IDE, Allergy, User, Society, Bleeding, Autoimmune disease

In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.

Key Points: 
  • In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.
  • Bausch + Lomb activities at ASCRS:
    “Assessment of the Spectacle Independence and Visual Outcomes Following Bilateral Implantation of a Novel Toric IOL* Among Cataract Patients.” Harasymowycz et al.
  • “Outcomes of an Ultra-Low Cylinder Powered (0.90 D) Toric versus Non-Toric IOL in Low Astigmatic Patients Undergoing Cataract Surgery.” Muzychuk et al.
  • “Quality of Vision and Clinical Outcomes of a Novel Trifocal IOL* Implanted Bilaterally After Cataract Surgery: A Canadian Multicenter Study.” Harasymowycz et al.